Cat's Claw

Cat's claw inhibits CYP3A4 in vitro. A case report of a 45-year-old HIV-positive woman documented dramatically elevated trough concentrations of atazanavir (4× increase), ritonavir (6.6× increase), and saquinavir (5.3× increase) when she took cat's claw concurrently. These increases reversed within 15 days of cat's claw discontinuation, confirming CYP3A4 inhibition as the mechanism. Additionally, cat's claw has PXR-activating potential which may induce CYP3A4 with prolonged use, creating a complex bidirectional interaction.

Avoid concurrent use with HIV protease inhibitors. If cat's claw has been taken, check drug plasma levels before next dose. Ritonavir itself inhibits CYP3A4, making the combination particularly unpredictable. Advise HIV patients to disclose all herbal supplement use to their prescriber. Levels should be re-checked 2 weeks after discontinuing cat's claw.

Cat's claw contains tetracyclic oxindole alkaloids (TOAs) including rhynchophylline, which inhibits platelet aggregation through multiple pathways including thromboxane A2 synthesis inhibition. Additionally, CYP3A4 inhibition by cat's claw may increase plasma levels of direct oral anticoagulants (apixaban, rivaroxaban) that undergo CYP3A4 metabolism. The combined pharmacodynamic antiplatelet effect and pharmacokinetic CYP3A4 inhibition potentiate anticoagulant effect and increase bleeding risk.

Monitor for signs of bleeding if cat's claw is used with anticoagulants. INR monitoring for warfarin users; check anti-Xa levels for LMWH. Discontinue cat's claw at least 2 weeks before scheduled surgery. Advise patients to avoid this combination without medical supervision.

Cat's claw alkaloids, particularly hirsutine and rhynchophylline, exert hypotensive effects via calcium channel blockade in vascular smooth muscle and a central antihypertensive mechanism. Rhynchophylline inhibits L-type calcium channel activity, leading to vasodilation similar in mechanism to dihydropyridine CCBs. Additive blood pressure lowering with prescribed antihypertensives can cause symptomatic hypotension, particularly in elderly patients.

Monitor blood pressure when initiating or discontinuing cat's claw in patients on antihypertensive therapy. Advise patients to report dizziness, lightheadedness, or falls. May need to reduce antihypertensive dose during concurrent use. Contraindicated in patients prone to hypotension.

Cat's claw is a potent immunostimulant that activates macrophages, enhances phagocytosis, increases leukocyte mobility, and stimulates lymphocyte proliferation and cytokine production. This immunostimulatory activity directly opposes the mechanism of action of immunosuppressant drugs, potentially leading to transplant rejection or flares of autoimmune disease. Concurrent CYP3A4 inhibition may also increase plasma levels of cyclosporine and tacrolimus, complicating dosing.

Contraindicated in transplant patients and those on immunosuppressants for autoimmune conditions. Cat's claw must not be used with cyclosporine or tacrolimus. Advise patients awaiting transplant or with autoimmune disease (rheumatoid arthritis, lupus, inflammatory bowel disease) to avoid cat's claw.

Rhynchophylline, an oxindole alkaloid in cat's claw, inhibits platelet aggregation by inhibiting thromboxane synthesis and platelet activating factor (PAF) pathways. Combined with aspirin (COX-1 inhibitor) or clopidogrel (P2Y12 inhibitor), the antiplatelet effect may be additive. Combined NSAIDs and cat's claw elevate GI bleeding risk. These effects are pharmacodynamic and unrelated to CYP metabolism.

Use caution when combining cat's claw with aspirin, clopidogrel, or NSAIDs. Monitor for signs of unusual or prolonged bleeding. Discontinue cat's claw at least 2 weeks before elective surgical procedures. Advise patients to report unusual bruising or prolonged bleeding times.

Uncaria tomentosa exerts anti-inflammatory effects through NF-kB pathway inhibition, suppression of TNF-alpha production, and modulation of prostaglandin synthesis pathways. These anti-inflammatory mechanisms partially overlap with those of NSAIDs (COX-1 and COX-2 inhibition). While this may produce beneficial additive anti-inflammatory effects for conditions such as rheumatoid arthritis, concurrent use also carries additive risks of gastrointestinal adverse effects (ulceration, bleeding) since both agents can inhibit prostaglandin-mediated gastroprotection.

If co-prescribing cat's claw with NSAIDs, consider gastroprotection with a PPI particularly in high-risk patients (age over 65, history of GI ulcer, concurrent corticosteroids). Monitor for GI adverse effects. Advise patients that additive GI risks exist even without a direct pharmacokinetic interaction.

Uncaria tomentosa extracts have demonstrated antidiabetic activity in experimental NAFLD models, improving insulin sensitivity and reducing hepatic inflammation via NF-kB and TNF-alpha pathways. Its oxindole alkaloids and triterpenoids may influence glucose metabolism and insulin signaling. Concurrent use with antidiabetic medications (especially insulin, sulfonylureas, and meglitinides) may produce additive blood glucose lowering, increasing the risk of hypoglycemia.

Monitor blood glucose levels more frequently when patients are using cat's claw alongside antidiabetic medications. Educate patients about signs and symptoms of hypoglycemia. Consider dose adjustment of antidiabetic medications if clinically significant additive glucose lowering is observed.

Cat's claw (Uncaria tomentosa) potently inhibits TNF-alpha production via NF-kB pathway suppression. TNF inhibitor biologics (adalimumab, etanercept, infliximab) specifically block TNF-alpha to treat autoimmune conditions including rheumatoid arthritis and Crohn's disease. Concurrent use creates pharmacodynamic overlap with additive immunomodulatory or immunosuppressive effects, potentially increasing the risk of opportunistic infections, impaired immune surveillance against malignancy, or unpredictable immune dysregulation.

Advise patients on TNF inhibitor biologic therapy to avoid cat's claw without specialist approval. Notify the prescribing rheumatologist or gastroenterologist if the patient is using cat's claw as a self-prescribed supplement. Monitor for signs of increased immunosuppression or opportunistic infections.

Preliminary in vitro evidence and a published case report indicate cat's claw may inhibit CYP3A4, the enzyme responsible for metabolising approximately 50% of all clinical drugs. In a documented case, serum trough concentrations of atazanavir, ritonavir, and saquinavir increased in an HIV-positive patient taking cat's claw, attributed to CYP3A4 inhibition. This interaction may affect other narrow therapeutic index CYP3A4 substrates including immunosuppressants (sirolimus), statins (simvastatin, lovastatin), and benzodiazepines (triazolam, alprazolam), as well as calcium channel blockers.

Monitor plasma concentrations of CYP3A4 substrates with narrow therapeutic indices when co-administering cat's claw. Reduce substrate dose if toxicity or supra-therapeutic levels are detected. Exercise particular vigilance in transplant patients on calcineurin inhibitors. While the inhibition appears relatively low-grade, it is clinically relevant for drugs with steep concentration-toxicity relationships.

Uncaria tomentosa has been described as having mild diuretic properties in South American traditional medicine, attributed to its alkaloid and glycoside constituents. Although systematic clinical reviews found no specific controlled studies evaluating diuretic activity of U. tomentosa in humans, traditional usage patterns and pharmacological plausibility suggest additive diuresis when combined with pharmaceutical diuretics. Combined use could lead to electrolyte imbalances (hypokalemia, hyponatremia) and volume depletion.

Monitor fluid balance and electrolytes in patients using cat's claw concurrently with diuretics, particularly in elderly patients or those with cardiac or renal disease. Advise adequate fluid intake and report symptoms of dehydration. Cat's claw products should be avoided before surgical procedures due to diuretic and antiplatelet properties.